combination therapy

Wool heart
Favicon Fierce Biotech

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Patients' disease stage, transthyretin knockdown levels and trial design have become focal points in debates around silencer-stabilizer combos.
Bausch Health headquarters formerly Valeant

Despite trial miss, Bausch + Lomb advances combo to ph. 3

Aug 25, 2026 10:46am
Kelun

Kelun's sac-TMT win offers blueprint for Merck's global gap

Jul 15, 2026 10:20am
checkered flag finish line racecar

FDA expands Padcev-Keytruda combo to more MIBC patients

Jul 10, 2026 1:10pm
yellow light street light traffic pause slow delay

Verastem mulls options on approved asset in pancreatic cancer

Jun 17, 2026 3:00pm
VanNaarden

Lilly oncology chief ‘blown away’ by new Jaypirca CLL data

Jun 15, 2026 8:25am